Company Overview of Zydus Pharmaceuticals (USA) Inc.
Zydus Pharmaceuticals (USA) Inc. develops, manufactures, and sells generic pharmaceutical products. It offers generic and reference products in tablet, capsule, soft gel, sterile liquid, injectable, inhaler, topical, and trans-dermal patch dosage forms. The company was incorporated in 2003 and is based in Pennington, New Jersey with locations in Memphis, Tennessee; and Ahmadabad, Vadodara, and Ankleshwar, India. Zydus Pharmaceuticals (USA) Inc. operates as a subsidiary of Cadila Healthcare Limited.
73 Route 31 North
Pennington, NJ 08534
Founded in 2003
Key Executives for Zydus Pharmaceuticals (USA) Inc.
Chief Executive Officer, President and Chief Executive Officer of Zydus Pharmaceuticals
Compensation as of Fiscal Year 2014.
Zydus Pharmaceuticals (USA) Inc. Key Developments
Cadila Healthcare and Zydus Pharmaceuticals (USA), Inc. Enter into Settlement Agreement with Depomed on Gralise
Apr 15 14
Cadila Healthcare and Zydus Pharmaceuticals (USA) Inc. have entered into a settlement agreement with Depomed Inc. to settle their ongoing patent infringement litigation related to Gralise (gabapentin) 300 mg and 600 mg tablets. The settlement permits Cadila and Zydus to begin selling generic versions of Gralise on January 1, 2024, or earlier under certain circumstances. The agreement is subject to review by the US Department of Justice and the Federal Trade Commission, and entry of an order dismissing the litigation by the US District Court for the District of New Jersey.
Warner Chilcott Company Announces Tentative Agreement with Zydus Pharmaceuticals USA Inc. and Cadila Healthcare Limited to Settle Asacol HD Patent Challenge Litigation
Dec 11 13
Actavis plc announced that it its subsidiary, Warner Chilcott Company, LLC, has entered into an agreement in principle with Zydus Pharmaceuticals USA Inc. and Cadila Healthcare Limited to settle all outstanding patent litigation related to Zydus' generic version of Asacol(R) HD (mesalamine) delayed-release tablets. The agreement remains subject to preparation and execution of definitive documentation. Under the terms of the agreement in principle, Warner Chilcott Company will grant Zydus a royalty-bearing license to market its generic Asacol(R) HD beginning on November 15, 2015 or earlier under certain circumstances, following receipt by Zydus of final approval from the U.S. Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for generic Asacol(R) HD. Alternatively, if Zydus does not receive FDA approval of its generic Asacol(R) HD by July 1, 2016, Zydus will be permitted to launch an authorized generic version of Actavis' product beginning on July 1, 2016.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries